LipidArt Research and Development

LipidArt is a Hungarian biotechnology company focused on the discovery and development of membrane-lipid therapy to treat metabolic and degenerative diseases. The company's research centers on modulating the physical state of cell membranes to regulate the expression of molecular chaperones, specifically heat shock proteins (HSPs). Their lead drug candidate, BGP-15, is a small molecule HSP70 co-inducer that has demonstrated potential in clinical trials for type 2 diabetes and insulin resistance. Beyond metabolic health, LipidArt explores the application of its technology in neuroprotection, muscle wasting disorders, and dermatology. The company operates as a research-intensive entity, often collaborating with the Biological Research Centre in Szeged.